Severe weight gain induced by combination treatment with risperidone and paroxetine.

Abstract:

:Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetine and risperidone. Retrospectively, we identified two patients treated with a combination of risperidone and paroxetine therapy, and analyzed their medical records. During a 3-month period of monotherapy with risperidone, the changes in body weight were +/- 0.0 kg in Patient 1 and -2.0 kg in Patient 2. In contrast, during combination therapy with paroxetine and risperidone, the body-weight changes were +14.0 kg in Patient 1 (after 4 months) and +13.5 kg in Patient 2 (after 5 months). In addition, diabetes mellitus was observed in Patient 2. Regarding the mechanism of severe weight gain in these two patients, we speculate a drug-drug interaction involving inhibition of the cytochrome P450 enzyme 2D6 (CYP4502D6) by paroxetine.

journal_name

Clin Neuropharmacol

authors

Fukui H,Murai T

doi

10.1097/00002826-200209000-00009

keywords:

subject

Has Abstract

pub_date

2002-09-01 00:00:00

pages

269-71

issue

5

eissn

0362-5664

issn

1537-162X

journal_volume

25

pub_type

杂志文章
  • Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.

    abstract::Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

    更新日期:1998-09-01 00:00:00

  • Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.

    abstract:BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e318206785a

    authors: Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

    更新日期:2011-01-01 00:00:00

  • Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.

    abstract:OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000058

    authors: Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

    更新日期:2015-01-01 00:00:00

  • Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

    abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013e31827db49b

    authors: Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

    更新日期:2013-01-01 00:00:00

  • United States experience and perspectives with trazodone.

    abstract::In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00002826-198901001-00003

    authors: Fabre LF

    更新日期:1989-01-01 00:00:00

  • Memory deficits of aged male rats can be improved by pyrimidine nucleosides and n-acetyl-glutamine.

    abstract::The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199008000-00002

    authors: Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

    更新日期:1990-08-01 00:00:00

  • The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis.

    abstract::The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intraveno...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200105000-00010

    authors: Hilkevich O,Drory VE,Chapman J,Korczyn AD

    更新日期:2001-05-01 00:00:00

  • Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.

    abstract::The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00002826-200003000-00007

    authors: Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

    更新日期:2000-03-01 00:00:00

  • Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans.

    abstract::The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00005

    authors: Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

    更新日期:1993-04-01 00:00:00

  • Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.

    abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199508000-00009

    authors: Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

    更新日期:1995-08-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I.

    abstract::The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal co...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199706000-00011

    authors: Toren P,Silbergeld A,Eldar S,Laor N,Wolmer L,Koren S,Weitz R,Inbar D,Reiss A,Eshet R,Weizman R

    更新日期:1997-06-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.

    abstract::Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Grözinger M,Härtter S,Hiemke C,Griese EU,Röschke J

    更新日期:1998-03-01 00:00:00

  • Medical treatment of patients with infantile spasms.

    abstract::Infantile spasms are the main feature in West syndrome, an age-related epilepsy syndrome that affects 1 in every 2,000-4,000 infants. The authors provide a comprehensive review of the literature about infantile spasms and their therapy. In the United States, the drug of choice for infantile spasms, at least the crypto...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200203000-00001

    authors: Mikati MA,Lepejian GA,Holmes GL

    更新日期:2002-03-01 00:00:00

  • Treatment of psychogenic polydipsia with acetazolamide: a report of 5 cases.

    abstract:OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318205070b

    authors: Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

    更新日期:2011-01-01 00:00:00

  • L-tyrosine pharmacotherapy of schizophrenia: preliminary data.

    abstract::The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199402000-00006

    authors: Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

    更新日期:1994-02-01 00:00:00

  • Relief of intractable posthypoxic myoclonus after administration of agomelatine.

    abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182613e06

    authors: González de la Aleja J,Saiz-Díaz RA,De la Peña P

    更新日期:2012-09-01 00:00:00

  • Benzodiazepine withdrawal seizures: analysis of 48 case reports.

    abstract::Various reactions to benzodiazepine withdrawal have been widely described. Among these, seizures have occasionally occurred on abrupt withdrawal. Our own experience of 48 cases of seizures suspected to have been caused by benzodiazepine withdrawal and reported to the Adverse Drug Reaction (ADR) Monitoring Center (1979...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Fialip J,Aumaitre O,Eschalier A,Maradeix B,Dordain G,Lavarenne J

    更新日期:1987-12-01 00:00:00

  • The syndrome of irreversible lithium-effectuated neurotoxicity.

    abstract:OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000150871.52253.b7

    authors: Adityanjee,Munshi KR,Thampy A

    更新日期:2005-01-01 00:00:00

  • Cytosolic and nuclear sex steroid receptors in meningioma.

    abstract::To determine the nature of the hormone dependency of meningioma, particularly whether progestin receptor (PR) and tumor growth are estrogen-dependent, we measured the cytosol estrogen receptor (ER) and PR separately by an exchange assay with [3H]R 2858 (for ER) and [3H]RU 27987 (for PR) in 21 meningiomas. We correlate...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198412000-00018

    authors: Moguilewsky M,Pertuiset BF,Verzat C,Philibert D,Philippon J,Poisson M

    更新日期:1984-01-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Midazolam in the treatment of refractory neonatal seizures.

    abstract::Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199619020-00005

    authors: Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

    更新日期:1996-04-01 00:00:00

  • Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication.

    abstract::In a double-blind, 4 week study, 42 chronic schizophrenic inpatients receiving antipsychotic and antiparkinsonian (AP) drugs for greater than 3 months were either switched to placebo or maintained on biperiden. In the majority of the patients no clinically apparent discomfort was observed, and only two of 21 placebo p...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198708000-00008

    authors: Wada Y,Koshino Y,Yamaguchi N

    更新日期:1987-08-01 00:00:00

  • Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center.

    abstract:RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31815cd960

    authors: Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

    更新日期:2008-11-01 00:00:00

  • Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

    abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000240941.13876.5E

    authors: Palakurthi HB,Parvin MM,Kaplan S

    更新日期:2007-01-01 00:00:00

  • Is history of depression a contraindication to treatment with tetrabenazine?

    abstract:OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.WNF.0000228369.25593.35

    authors: Kenney C,Hunter C,Mejia N,Jankovic J

    更新日期:2006-09-01 00:00:00

  • Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

    abstract::The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198604000-00005

    authors: Rascol A,Montastruc JL,Rascol O,Senard JM

    更新日期:1986-01-01 00:00:00

  • A study of salivary secretion in Parkinson's disease.

    abstract::Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Bagheri H,Damase-Michel C,Lapeyre-Mestre M,Cismondo S,O'Connell D,Senard JM,Rascol O,Montastruc JL

    更新日期:1999-07-01 00:00:00